Effect of Fasting, Endogenous GLP-1 Secretion on B-cell Response to Intravenous Glucose

Overview

About this study

The purpose of this study is to determine the effect of GLP-1 in priming β-cells for insulin secretion.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

BMI 18 – 35 Kg/M2
Fifteen patients with normal glucose tolerance and fifteen with impaired fasting glucose
Participants will be in good health
Stable weight
Not engaged in regular vigorous exercise
No history of diabetes or of prior therapy with antidiabetic medication
No history of chronic disease
No prior abdominal surgery other than cholecystectomy or appendectomy

Exclusion Criteria:

Subjects < 20 years of age or > 65 years of age

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Adrian Vella, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Adrian Vella, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials